Ipsen in Ireland
Development and manufacturing
The Dublin site, which opened in 1989, is the Group’s center for the production and development of peptides (lanreotide and triptorelin). In addition to the development of peptide active ingredients, Dublin also has responsibility for developing small molecule active ingredients, in particular with regard to the development of manufacturing processes, large-scale manufacturing, quality control and analytic development.
Message from the chairman
3 questions to Marc de Garidel, Chairman & CEO
22 November 2013 - Paris (France)
The 22nd Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Jean Decety (University of Chicago, Chicago,…